Search
tesaglitazar (Galida)
Glitazar in clinical trials
Indications: diabetes mellitus type 2
Dosage: * 0.5-3.0 mg PO QD * phase 3 clinical trials for 1.0 & 2.0 mg PO QD
Adverse effects:
- may be more likely than thiazolidinediones to cause edema & heart failure * 60% discontinuation of drug at 3 mg QD
Mechanism of action:
1) glitazar, a so-called 2 in 1 drug
a) improves blood glucose similar to thiazolidinediones
b) improves lipid profile similar to fibrates
- lowers triglycerides up to 40% (3 mg QD)
- lowers LDL up to 17% (3 mg QD)
2) activates both PPAR-alpha & PPAR-gamma
a) activation of PPAR-gamma decreases plasma glucose & free fatty acid concentrations
b) activation of PPAR-alpha receptors decreases plasma triglyceride & increases plasma HDL cholesterol
Interactions
drug interactions
drug adverse effects of hypoglycemic agents
General
glitazar
Database Correlations
PUBCHEM cid=208901
References
- Prescriber's Letter 12(9): 2005
Diabetes Drugs on the Horizon: Investigational Drug:
Muraglitazar (Pargluva)
Detail-Document#: 210905
(subscription needed) http://www.prescribersletter.com
- Internal Medicine News 38(16) August 2005